ESR1 and breast cancer: In addition, high level of Notch1 mRNA predicted for poor recurrence-free survival (RFS) (n = 230, HR = 1.81, p = 0.0199) in basal-like BC patients with chemotherapy (Fig. 1D), as well as ER + BC parients (Supplement 1A,B) and Her2+ BC patients (Supplement 1C,D), with mRNA expression of CD73 also correlating with poor RFS (n = 230, HR = 1.98, p = 0.007) (Fig. 1E).